Similarly, chemical glutaminase inhibitor CB-839 (currently in clinical trials for non-Hodgkin lymphomas) exhibited synergistic or additive effects with NCT-503 for selected dose combinations in four out of five cell lines (Figure S5B). Here, GLS is linked to non-Hodgkin lymphoma.